 SAN DIEGO, Calif. and CALGARY, Alberta , June 15, 2020 CNW -- Oncolytics Biotech Inc. ONCY ONC.TO, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market ATM equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to 40 million over the course of the next 25 months. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics the option to efficiently tap into the financial markets as needed to support ongoing business development activities and clinical trials, while bolstering managements ability to negotiate potential business development agreements from a position of financial strength. 